Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2026-04-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（阎丽明）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director (阎丽明) of 山西锦波生物医药股份有限公司 for the year 2025. It includes comprehensive information about the director's duties, attendance at board and committee meetings, oversight of financial audits, internal controls, related party transactions, appointment of auditors, remuneration, and other governance matters. The document is lengthy (8994 characters) and contains substantive content about the company's governance and oversight activities during the fiscal year 2025. It is not a brief announcement or a certification letter but a full report on the independent director's annual duties and observations. This type of document fits best under the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on the independent director's report rather than full financial statements or audit opinions. Therefore, the classification is MANG with high confidence.
2026-04-28 Chinese
第四届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 20th meeting of the 4th Board of Directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes multiple agenda items such as approval of the 2025 Board Work Report, 2025 General Manager Work Report, 2025 Annual Report and its summary, 2025 financial reports, audit reports, internal control reports, remuneration plans, and other governance-related reports. The document repeatedly references that the full reports are disclosed on the Beijing Stock Exchange website and that these items will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal board meeting resolution announcement summarizing the approval of various reports and plans. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document is not the full Annual Report (10-K) or Audit Report (AR) itself, nor is it a simple announcement of report publication (RPA) because it contains substantive board resolutions and voting results. Therefore, the best classification is MANG with high confidence.
2026-04-28 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled "董事、高级管理人员薪酬管理制度" which translates to "Board and Senior Management Remuneration Management System." It details the remuneration policies, principles, structure, adjustments, and clawback provisions for the company's directors and senior management. It includes references to the board's approval, shareholder meeting submission, and compliance with laws and regulations. The document is a detailed policy or report on remuneration management rather than a simple announcement or a proxy solicitation. It is not a full annual or interim financial report, nor is it a certification or voting result. It fits best under the category of Remuneration Information, which covers reports detailing compensation for top executives and directors.
2026-04-28 Chinese
董事会关于2025年度独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence self-assessment of the company's independent directors for the year 2025. It details the evaluation criteria and confirms the independence of the directors based on regulatory requirements from the China Securities Regulatory Commission. The content is focused on governance and compliance related to board members' independence, not financial results, audit opinions, or shareholder voting outcomes. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short but contains substantive governance content, not merely an announcement or certification, so it is not RPA or RNS.
2026-04-28 Chinese
关于注销2025年股权激励计划部分股票期权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the cancellation of part of the 2025 stock option incentive plan. It details the board resolutions, supervisory committee opinions, legal opinions, and independent financial advisor opinions related to the cancellation of unexercised stock options. The document includes specific dates, meeting resolutions, and regulatory compliance references. It is not a full financial report, audit report, or earnings release, but rather a formal announcement about changes in the company's stock option incentive plan. This fits the category of a Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through stock option cancellations. The document length is 4201 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the most appropriate classification is CAP.
2026-04-28 Chinese
回购股份报告书公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the company's plan to repurchase its own shares, including the purpose, scale, price range, funding sources, implementation period, and risk disclosures. It includes specifics about the board meeting resolutions authorizing the repurchase and compliance with regulatory guidelines. The content focuses on the share repurchase program rather than financial results, management changes, or legal proceedings. This matches the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares. The document length is over 6,000 characters and contains substantive details about the repurchase plan, not just an announcement of a report or a brief notice, so it is not an RPA or RNS. Therefore, the correct classification is POS with high confidence.
2026-04-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.